Altered expression of methylenetetrahydrofolate reductase modifies response to methotrexate in mice

Pharmacogenetics and Genomics

Volumn 18, Issue 7, 2008, Pages 577-589

  Celtikci, Basak ^a   Leclerc, Daniel ^a   Lawrance, Andrea K ^a   Deng, Liyuan ^a   Friedman, Hana C ^b   Krupenko, Natalia I ^c   Krupenko, Sergey A ^c   Melnyk, Stepan ^d   James, S Jill ^d   Peterson, Alan C ^b   Rozen, Rima ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

Hematocrit; Hemoglobin; Homocysteine; Methotrexate; Methylenetetrahydrofolate reductase; Polymorphism; Red blood cells; Thymidylate

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENOSINE; CYSTEINE; CYSTEINYLGLYCINE; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; FOLIC ACID; GLUTATHIONE; HEMOGLOBIN; HOMOCYSTEINE; METHIONINE; METHOTREXATE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; SODIUM CHLORIDE; THYMIDINE TRIPHOSPHATE; IMMUNOSUPPRESSIVE AGENT; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

AMINO ACID BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; CELL COUNT; CONTROLLED STUDY; DRUG RESPONSE; ERYTHROCYTE; FEMALE; FOLIC ACID BLOOD LEVEL; HEMATOCRIT; HYPERHOMOCYSTEINEMIA; LEUKOCYTE; LIVER TOXICITY; MALE; METABOLITE; MOUSE; NEPHROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; BLOOD; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED DISORDER; GENE EXPRESSION; GENETICS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; MOUSE MUTANT; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALIA; MUS; MUS MUSCULUS;

ANIMALS; CELLS, CULTURED; FEMALE; GENE EXPRESSION; HOMOCYSTEINE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 53049103788     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32830058aa     Document Type: Article

References (43)

1. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
2. Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci U S A 1998; 95:13217-13220.
3. Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A 2002; 99:5606-5611.
4. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics 2001; 1:189-201.
5. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57:1098-1102.
6. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A 1999; 96:12810-12815.
7. Longo-Sorbello GS, Bertino JR. Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica 2001; 86:121-127.
8. Fiskerstrand T, Ueland PM, Refsum H. Folate depletion induced by methotrexate affects methionine synthase activity and its susceptibility to inactivation by nitrous oxide. J Pharmacol Exp Ther 1997; 282:1305-1311.
9. Winter-Vann AM, Kamen BA, Bergo MO, Young SG, Melnyk S, James SJ, et al. Targeting ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc Natl Acad Sci U S A 2003; 100:6529-6534.
10. Kremer JM. Methotrexate pharmacogenomics. Ann Rheum Dis 2006; 65:1121-1123.
11. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase c677t polymorphism. Blood 2001; 98:231-234.
12. Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006; 54:1366-1377.
13. Toffoli G, Veronesi A, Boiocchi M, Crivellari D. Mthfr gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (cmf). Ann Oncol 2000; 11:373-374.
14. Toffoli G, Cecchin E. Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy. J Chemother 2004; 16 (Suppl 4):31-35.
15. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI. Effect of the methylenetetrahydrofolate reductase c677t polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004; 96:134-144.
16. Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, et al. Effect of methylenetetrahydrofolate reductase 677c-> t polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003; 103:294-299.
17. Chiusolo P, Reddiconto G, Casorelli I, Laurenti L, Sora F, Mele L, et al. Preponderance of methylenetetrahydrofolate reductase c677t homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002; 13:1915-1918.
18. Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S, Lussier-Cacan S, et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001; 10:433-443.
19. Ghandour H, Chen Z, Selhub J, Rozen R. Mice deficient in methylenetetrahydrofolate reductase exhibit tissue-specific distribution of folates. J Nutr 2004; 134:2975-2978.
20. Margolis S, Philips FS, Sternberg SS. The cytotoxicity of methotrexate in mouse small intestine in relation to inhibition of folic acid reductase and of DNA synthesis. Cancer Res 1971; 31:2037-2046.
21. Durand P, Fortin LJ, Lussier-Cacan S, Davignon J, Blache D. Hyperhomocysteinemia induced by folic acid deficiency and methionine load-applications of a modified hplc method. Clin Chim Acta 1996; 252:83-93.
22. Cross DR, Miller BJ, James SJ. A simplified hplc method for simultaneously quantifying ribonucleotides and deoxyribonucleotides in cell extracts or frozen tissues. Cell Prolif 1993; 26:327-336.
23. Denarier E, Forghani R, Farhadi HF, Dib S, Dionne N, Friedman HC, et al. Functional organization of a schwann cell enhancer. J Neurosci 2005; 25:11210-11217.
24. Goyette P, Christensen B, Rosenblatt DS, Rozen R. Severe and mild mutations in cis for the methylenetetrahydrofolate reductase (mthfr) gene, and description of five novel mutations in mthfr. Am J Hum Genet 1996; 59:1268-1275.
25. Goyette P, Pai A, Milos R, Frosst P, Tran P, Chen Z, et al. Gene structure of human and mouse methylenetetrahydrofolate reductase (mthfr). Mamm Genome 1998; 9:652-656.
26. Leclerc D, Darwich-Codore H, Rozen R. Characterization of a pseudogene for murine methylenetetrahydrofolate reductase. Mol Cell Biochem 2003; 252:391-395.
27. Kuo KC, McCune RA, Gehrke CW, Midgett R, Ehrlich M. Quantitative reversed-phase high performance liquid chromatographic determination of major and modified deoxyribonucleosides in DNA. Nucleic Acids Res 1980; 8:4763-4776.
28. Trasler J, Deng L, Melnyk S, Pogribny I, Hiou-Tim F, Sibani S, et al. Impact of dnmt1 deficiency, with and without low folate diets, on tumor numbers and DNA methylation in min mice. Carcinogenesis 2003; 24:39-45.
29. Melnyk S, Pogribna M, Pogribny IP, Yi P, James SJ. Measurement of plasma and intracellular s-adenosylmethionine and s-adenosylhomocysteine utilizing coulometric electrochemical detection: alterations with plasma homocysteine and pyridoxal 5′-phosphate concentrations. Clin Chem 2000; 46:265-272.
30. Schmitz JC, Grindey GB, Schultz RM, Priest DG. Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationship to dideazatetrahydrofolate sensitivity. Biochem Pharmacol 1994; 48:319-325.
31. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000; 20:6920-6926.
32. Mangiagalli A, Samuele A, Armentero MT, Bazzini E, Nappi G, Blandini F. Effects of homocysteine on apoptosis-related proteins and anti-oxidant systems in isolated human lymphocytes. Eur J Biochem/FEBS 2004; 271:1671-1676.
33. Chen Z, Schwahn BC,Wu Q, He X, Rozen R. Postnatal cerebellar defects in mice deficient in methylenetetrahydrofolate reductase. Int J Dev Neurosci 2005; 23:465-474.
34. Chwatko G, Boers GH, Strauss KA, Shih DM, Jakubowski H. Mutations in methylenetetrahydrofolate reductase or cystathionine beta-synthase gene, or a high-methionine diet, increase homocysteine thiolactone levels in humans and mice. FASEB J 2007; 21:1707-1713.
35. Kerkeni M, Tnani M, Chuniaud L, Miled A, Maaroufi K, Trivin F. Comparative study on in vitro effects of homocysteine thiolactone and homocysteine on huvec cells: evidence for a stronger proapoptotic and proinflammative homocysteine thiolactone. Molec Cell Biochem 2006; 291:119-126.
36. Jakubowski H. The molecular basis of homocysteine thiolactone-mediated vascular disease. Clin Chem Lab Med 2007; 45:1704-1716.
37. van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA, et al. The c677t mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001; 44:2525-2530.
38. Prudova A, Bauman Z, Braun A, Vitvitsky V, Lu SC, Banerjee R. S-adenosylmethionine stabilizes cystathionine beta-synthase and modulates redox capacity. Proc Natl Acad Sci U S A 2006; 103:6489-6494.
39. Likogianni V, Janel N, Ledru A, Beaune P, Paul JL, Demuth K. Thiol compounds metabolism in mice, rats and humans: comparative study and potential explanation of rodents protection against vascular diseases. Clin Chim Acta 2006; 372:140-146.
40. Mudd SH, Finkelstein JD, Irreverre F, Laster L. Transsulfuration in mammals. Microassays and tissue distributions of three enzymes of the pathway. J Biol Chem 1965; 240:4382-4392.
41. Schwahn BC, Laryea MD, Chen Z, Melnyk S, Pogribny I, Garrow T, et al. Betaine rescue of an animal model with methylenetetrahydrofolate reductase deficiency. Biochem J 2004; 382:831-840.
42. Hoekstra M, Haagsma CJ, Doelman CJ, van de Laar MA. Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate. Ann Rheum Dis 2005; 64:141-143.
43. Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21:3084-3091.